# US 2021/0079093 A1 · Methods for achieving therapeutically effective doses of anti-cd47 agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079093 A1
- Document ID: US20210079093A1
- Status: Published application
- Kind: A1
- Application number: 17/102,183
- Filed: 2020-11-23
- Published: 2021-03-18
- Earliest claimed: 2013-03-15
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Stephen Willingham; Maureen Howard; Jie Liu; Ravindra Majeti; Susan Sweeney Prohaska; Anne Kathrin Volkmer; Jens-Peter Volkmer; Irving L. Weissman
- Web page: https://patentgrep.com/patent/US20210079093A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 38/1816: {Erythropoietin [EPO]}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.

## Claims

### Claim 1

A method for treating a human subject with cancer, the method comprising:
(a) administering a sub-therapeutic dose of from 0.1 mg/kg to 10 mg/kg of an anti-CD47 antibody, wherein the sub-therapeutic dose is sufficient to increase production of reticulocytes; and
(b) administering a therapeutically effective dose of an anti-CD47 antibody; wherein step (b) is performed in a range of from 5 to 9 days after beginning step (a).

### Claim 2 (depends on 1)

The method of claim 1, wherein the sub-therapeutic dose is from 1 mg/kg to 5 mg/kg.

### Claim 3 (depends on 1)

The method of claim 1, wherein the sub-therapeutic dose is from 1 mg/kg to 3 mg/kg.

### Claim 4 (depends on 1)

The method of claim 1, wherein step (b) is performed in a range from 3 days to 21 days after beginning step (a); and wherein for step (b) a series of therapeutically effective doses is administered.

### Claim 5 (depends on 4)

The method of claim 4, wherein the series of therapeutically effective doses is administered at a dose from 10 mg/kg to 40 mg/kg.

### Claim 6 (depends on 1)

The method of claim 1, wherein the anti-CD47 antibody is 5F9-G4.

### Claim 7

A method for treating a human subject with cancer, the method comprising:
(a) administering a sub-therapeutic dose of 1 mg/kg of an anti-CD47 antibody, wherein the sub-therapeutic dose is sufficient to increase production of reticulocytes; and
(b) administering a series of therapeutically effective doses of an anti-CD47 antibody of escalating concentration at doses from 10 mg/kg to about 30 mg/kg; wherein step (b) is administered semi-weekly, starting 8 days after beginning step (a).

### Claim 8 (depends on 7)

The method of claim 7, wherein the anti-CD47 antibody is 5F9-G4.

### Claim 9 (depends on 7)

The method of claim 7, wherein the cancer is a pre-malignant condition.

### Claim 10 (depends on 7)

The method of claim 7, wherein the cancer is a hematologic cancer.

### Claim 11 (depends on 10)

The method of claim 10, wherein the hematologic cancer is a leukemia.

### Claim 12 (depends on 11)

The method of claim 11, wherein the leukemia is acute myeloid leukemia (AML).

### Claim 13 (depends on 10)

The method of claim 10, wherein the hematologic cancer is a lymphoma.

### Claim 14

A method for treating a human subject with cancer, the method comprising:
(a) administering a series of two sub-therapeutic dose of 1 mg/kg of an anti-CD47 antibody, wherein the sub-therapeutic dose is sufficient to increase production of reticulocytes; and
(b) administering a series of therapeutically effective doses of an anti-CD47 antibody of escalating concentration at doses from 10 mg/kg to about 30 mg/kg; wherein step (b) is administered semi-weekly, starting 8 days after beginning step (a).

### Claim 15 (depends on 14)

The method of claim 14, wherein the anti-CD47 antibody is 5F9-G4.

### Claim 16 (depends on 14)

The method of claim 14, wherein the cancer is a pre-malignant condition.

### Claim 17 (depends on 14)

The method of claim 14, wherein the cancer is a hematologic cancer.

### Claim 18 (depends on 17)

The method of claim 17, wherein the hematologic cancer is a leukemia.

### Claim 19 (depends on 18)

The method of claim 18, wherein the leukemia is acute myeloid leukemia (AML).

### Claim 20 (depends on 14)

The method of claim 14, wherein the hematologic cancer is a lymphoma.
